-
HQ Pharma and Shanxi HCXF Partner to Expand Oral Soluble Film R&D and Production
•
China-based firms HQ Pharma and Shanxi HCXF Pharmaceutical Co., Ltd have agreed to jointly expand their one-stop oral soluble film research and development (R&D) and production services. The collaboration aims to enhance their capabilities in this innovative drug delivery system, with no financial details disclosed. Advantages of Oral Soluble FilmsOral…
-
Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform
•
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ). The agreement grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite platform and…
-
Sumitomo Pharma Secures Rights to Vibegron for Asian Markets
•
Japan-based Sumitomo Pharma Co., Ltd has signed a sub-license deal with compatriot firm Kyorin Pharmaceutical Co., Ltd, focusing on the over-active bladder (OAB) therapy Gemtesa (vibegron). This strategic agreement grants Sumitomo development, manufacturing, and commercialization rights to vibegron in key Asian markets, including Taiwan and Hong Kong in China, Singapore,…
-
Suzhou Porton Biologics Partners with Bennu Biotherapeutics for Gene and Cell Therapies
•
China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has entered into a strategic partnership with compatriot firm Bennu Biotherapeutics, a T-cell therapy specialist based in Shanghai. The collaboration focuses on the area of gene and cell therapies (GCTs), with Porton providing comprehensive CDMO services to Bennu. The…
-
Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment
•
China-based Akeso Biopharma (HKG: 9926) has announced a strategic collaboration agreement with compatriot firm Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607). The partnership aims to accelerate the development of Akeso’s cadonilimab (AK104) in combination with Shanghai Pharmaceuticals’ SPH4336 for the treatment of well-differentiated liposarcoma (WDLS) and dedifferentiated liposarcoma (DDLS). About…
-
F-star Therapeutics’ Acquisition by invoX Pharma Cleared by CFIUS
•
UK biotech F-star Therapeutics, Inc. (NASDAQ: FSTX) has announced that it has received clearance from the Committee on Foreign Investment in the United States (CFIUS) for the all-cash acquisition by invoX Pharma Limited, a UK-based subsidiary of China’s Sino Biopharmaceutical Ltd (HKG: 1177). This clearance is a significant step towards…
-
Biocytogen’s YH008 Gets NMPA Approval for Phase I Study
•
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd has announced receiving approval from the China National Medical Products Administration (NMPA) to conduct an open-label Phase I dosage escalation study. The study will assess the safety, tolerability, and preliminary anti-tumor activity of YH008, an internally developed first-in-class PD-1 x CD40 bispecific antibody (BsAb)…
-
Heranova Closes $10M Seed Round for Women’s Health Solutions
•
Heranova Lifesciences Holding, a provider of women’s health solutions, has announced the successful closure of a seed financing round at USD 10 million. The round was co-led by Pivotal Bioventure Partners and Sinovation Ventures, with the proceeds earmarked for commercialization efforts in the Asia-Pacific region. This includes the market launch…
